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Abstract Erythropoietin (EPO) promotes the viability, prolif-
eration and differentiation of mammalian erythroid progenitor
cells via its specific cell surface receptor. The EPO receptor
(EPO-R) is a member of the cytokine receptor superfamily and is
comprised of one identified subunit which homodimerizes upon
ligand binding. To study the role of the intracellular domain of
the EPO-R in the endocytosis of EPO, we compared the rate and
extent of 125I-EPO endocytosis by wild type (wt) EPO-R and
five cytoplasmically truncated EPO-Rs: 1^251 EPO-R, 1^257
EPO-R, 1^267 EPO-R, 1^276 EPO-R and 1^306 EPO-R which
contain 4, 10, 20, 29 or 59 amino acids of the cytoplasmic
domain, respectively. We also studied an EPO-R mutant (PB)
which lacks amino acid residues 281^300 of the cytoplasmic
domain. The experiments were conducted in COS 7 cells
transfected with the EPO-R cDNAs and in Ba/F3 cells stably
expressing the wt EPO-R, 1^251 or 1^257 EPO-R. Cells
expressing wt EPO-R, PB EPO-R (v281^300), 1^276 EPO-R
or 1^306 EPO-R internalized approximately 50% of 125I-EPO
bound to the cell surface, while cells expressing 1^251, 1^257 or
1^267 EPO-R internalized only 25% of the bound 125I-EPO.
The steady-state expression levels of these latter receptors on the
cell surface were typically 2^5-fold higher than wt EPO-R. Our
data indicate that amino acid residues 267^276 (FEGLFTTHK)
of the EPO-R cytoplasmic domain may have a role in receptor
internalization. Metabolic labeling experiments suggest that in
transiently transfected COS 7 cells most of the wt EPO-R and
1^257 EPO-Rs do not exit the ER and may be degraded there.
The half-life of both receptors was essentially similar and was in
the range of 1 h. In Ba/F3 cells the mature Golgi processed 1^257
EPO-R was more stable than the corresponding form of the wt
EPO-R, possibly contributing to its higher cell surface expres-
sion.
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1. Introduction
Proliferation of immature red blood cells and their di¡er-
entiation into mature erythrocytes are mediated by erythro-
poietin (EPO). The erythropoietin receptor (EPO-R) [1] be-
longs to the superfamily of cytokine receptors which includes
the receptors for interleukins (IL) 2, 3, 4, prolactin, growth
hormone (GH) and leukemia inhibitory factor. These recep-
tors all have one transmembrane domain, four cysteine resi-
dues similarly spaced and a common WSXWS sequence motif
in their extracellular domain [2]. Unlike receptor tyrosine ki-
nases, the cytoplasmic domain of cytokine receptors is devoid
of kinase activity and is presumably phosphorylated by Janus
kinases (JAKs) following ligand binding [3]. Thus far, only
one subunit of the EPO-R has been identi¢ed, which homo-
dimerizes upon ligand binding [4,5]. EPO-Rs which lack the
entire cytoplasmic domain have been suggested to occur in
bone marrow [6] and to function as dominant negative regu-
lators of the EPO-R [7,8].
One striking property of the EPO-R is its low cell surface
expression, suggesting that cell surface levels of EPO-R may
be tightly controlled in order to regulate erythroid prolifera-
tion and di¡erentiation in response to physiological levels of
EPO under normal or hypoxic conditions. Both translational
[9,10] and posttranslational [11] mechanisms probably control
the steady-state levels of cell surface EPO-R. The latter may
include for example protein folding [11], protein stability and
receptor downregulation by internalization and ligand medi-
ated endocytosis. Structural features of the EPO-R which reg-
ulate its cell surface expression are still unclear. Accumulating
evidence suggests that e⁄cient internalization of membrane
receptors requires a speci¢c sequence(s) in the cytoplasmic
domain which may interact with auxiliary cellular molecules
[12^14]. The sequences include D-leucine based motifs [15,16]
and Tyr based motifs [13,17]. Identi¢cation of such sequences
is of extreme importance in view of their possible roles in
controlling surface as well as intracellular levels of the cell
surface receptors. The contribution of the EPO-R cytosolic
domain to cell surface EPO-R expression has not yet been
resolved.
The cytosolic domain of the GH receptor (GHR) [18] as
well as that of the prolactin receptor [19] contain sequence
motifs which are required for ligand endocytosis. Recently,
it was shown that the IL-2 L chain cytosolic domain contains
sequences that designate it for degradation after endocytosis
[20]. In this study we set forth to delineate cytoplasmic resi-
dues of the EPO-R that are involved in regulating cell surface
expression of the EPO-R and receptor mediated endocytosis
of EPO. We show that EPO-Rs containing at least 276 amino
acids endocytose ligand similarly to the full length wild type
(wt) EPO-R. On the other hand, EPO-Rs which are truncated
at cytoplasmic residues 251, 257 or 267 are expressed at higher
levels on the cell surface and internalize 125I-EPO approxi-
mately two-fold less than full length EPO-R. These ¢ndings
suggest that a motif required for receptor internalization may
occur between residues 267 and 276 of the EPO-R cytoplas-
mic domain.
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2. Materials and methods
2.1. Materials
Puri¢ed recombinant human EPO was a kind gift from Kirin, Ja-
pan. All other materials were obtained from sources previously listed
[21].
2.2. Antibodies
Rabbit antibodies directed against the cytoplasmic domain [22] or
the extracellular domain [23] of the murine EPO-R were used at a
1:500 dilution for immunoprecipitations, and at a dilution of 1:1000
for immunoblotting, as indicated.
2.3. Construction of mutant EPO-R cDNAs
1^251, 1^267 and 1^276 EPO-R were constructed using the PCR
method to insert a stop codon after amino acid residue 251 or 267 or
276 respectively, followed by an EcoRI restriction site for convenient
cloning into pXM [1]. The cDNAs of 1^251, 1^267 and 1^276 EPO-R
were generated by the PCR method, using the primer 5P-GAGTCGG-
TACCTGAAGCTAGGGCTGC-3P along with each of the following
primers: 5P-GAGGAATTCCTACCGGCGGTGGGACTG-3P ; 5P-
GACGAATTCATCCGCTCTCTGGGC-3P ; 5P-GAGGAATTCCTT-
GTGGGTGGTGAAGAGACC-3P for 1^251, 1^267 and 1^276 EPO-
R respectively. The structure of the plasmids was con¢rmed by DNA
sequencing. 1^257 and 1^306 EPO-Rs have been described elsewhere
[7]. The cDNA of PB EPO-R (v281^300) was a generous gift from Dr.
J. Ihle (Memphis, TN).
2.4. Cell culture and transfection
COS 7 cells were maintained in Dulbecco’s modi¢ed Eagle’s me-
dium supplemented with 10% fetal calf serum (FCS) (v/v). Cells were
cultured to 60% con£uence and were transiently transfected using the
DEAE dextran/chloroquine method [24] with 5 Wg of EPO-R cDNA
cloned in pXM [1]. 125I-EPO binding and internalization were deter-
mined 48 h after transfection.
Ba/F3 cell lines stably expressing 1^251 and 1^257 EPO-R were
generated as described [7]. Ba/F3 cell lines stably expressing the wt
EPO-R cDNA [25], 1^251 or 1^257 EPO-Rs in pXM were maintained
in RPMI supplemented with 10% FCS (v/v) and 0.25 U/ml EPO for
wt EPO-R or 10% conditioned medium from WEHI 3B cells as a
source of IL-3 for the truncated EPO-Rs.
2.5. Iodination of EPO, binding and internalization
Recombinant EPO was labeled using the iodine monochloride
method [26] and had a speci¢c activity of 4U106 cpm/pmol. Brie£y,
2.5 Wl of a 1.25 mg/ml solution of EPO in PBS was labeled by the
addition of 100 Wl of 200 mM sodium phosphate, 0.02% (v/v) Tween
20 at pH 7.4 and 1 mCi of Na125I. Two 5 Wl aliquots of 200 mM ICl
in 2 M NaCl were added at 1 min intervals while vortex mixing.
Radioiodinated EPO (125I-EPO) was separated from 125I by gel ¢ltra-
tion and cation exchange chromatography.
2.6. 125I-EPO binding
Cells (107 COS 7 cells, lifted from the plates by treatment with
15 mM EDTA pH 8.0 in PBS, or 2U106 Ba/F3 cells, cultured in
suspension) were washed twice in either DMEM or in RPMI, respec-
tively. Cells were incubated with 125I-EPO for 16 h at 4‡C, in a ¢nal
volume of 100 Wl, in the appropriate medium containing 10% FCS,
20 mM HEPES pH 7.4 (binding medium). After sedimentation of cells
through ice cold FCS, cell associated radioactivity and free 125I-EPO
were measured. Speci¢c binding was determined by subtracting the
cell associated radioactivity in the presence of unlabeled EPO
(100 nM) from that associated with the cells in the absence of excess
unlabeled ligand. To measure endocytosed 125I-EPO, the cell pellets
were further resuspended in 100 Wl of binding medium and incubated
for di¡erent time periods at 37‡C. Subsequently, the cells were sedi-
mented again through ice cold FCS, to remove dissociated 125I-EPO.
Cell pellets were then exposed to an acid wash (4% acetic acid in
PBS) for 2.5 min at 4‡C, and released, cell surface 125I-EPO was
separated from internalized ligand by a third centrifugation through
an FCS cushion. Speci¢c binding was de¢ned as the di¡erence be-
tween 125I-EPO bound to the cells in the absence and in the presence
of unlabeled EPO. Continuous uptake of 125I-EPO was measured by
incubating the cells with 125I-EPO for 90 min at 37‡C. Cell surface
bound and internalized 125I-EPO were determined as described.
2.7. Metabolic labeling, immunoprecipitation and endoglycosidase H
(Endo H) digestion
Ba/F3 cells expressing the EPO-R or COS 7 cells transiently trans-
fected with EPO-R cDNAs (2U106 cells for each time point) were
labeled with [35S]cysteine/methionine as previously described [25].
Subsequently cells were chased in the presence of non-labeled amino
acids for the indicated periods of time. Solubilization of the cells,
immunoprecipitation and digestion with Endo H were performed as
previously described [21,22].
2.8. Western blot analysis
Western blot analysis was performed as described previously [25].
3. Results
3.1. Endocytosis of 125I-EPO by wt EPO-R is similar in Ba/F3
and in COS 7 cells
A wealth of information has accumulated on signal trans-
duction and structure-function relationship of the EPO-R ex-
pressed in the pro B cell line Ba/F3. When these cells are
transfected with EPO-R cDNA, EPO can replace their need
for interleukin 3 (IL-3), thus rendering this system useful for
studying the EPO-R. Importantly, many properties of the
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Fig. 1. 125I-EPO internalization in Ba/F3 cells and in COS 7 cells
expressing the EPO-R. Ba/F3 cells expressing wt EPO-R and COS 7
cells transfected with wt EPO-R cDNA were incubated at 4‡C for
16 h in the appropriate binding medium containing 125I-EPO. Un-
bound ligand was removed by centrifugation through FCS. Cells
were then resuspended in binding medium and incubated at 37‡C
for di¡erent time periods (as indicated). Cells were then cooled to
4‡C, and centrifuged through an FCS layer. To quantify endocy-
tosed 125I-EPO, the cell pellets were treated with PBS containing 4%
acetic acid for 2.5 min, to dissociate surface bound ligand. Speci¢c
internalized (A) or surface bound (B) 125I-EPO was determined by
subtracting 125I-EPO counts in the presence of 100 nM unlabeled
EPO from the counts obtained in its absence. Values are presented
as percent of total surface and intracellular 125I-EPO at each time
point. The values represent the mean þ S.D. of two di¡erent experi-
ments, performed in triplicate.
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receptor are retained in transiently transfected COS 7 cells
(e.g. ligand binding a⁄nity and kinetics), thereby providing
a system in which the EPO-R can be readily analyzed [11].
Initially we demonstrated that 125I-EPO was internalized to a
similar extent and with similar kinetics by wt EPO-R, whether
stably expressed in Ba/F3 cells, or transiently expressed in
COS 7 cells (Fig. 1). Cells were incubated overnight with
125I-EPO at 4‡C. Unbound ligand was removed the following
day, and the cells were further incubated at 37‡C, for 0^20
min as indicated (Fig. 1). As can be observed, the rate and
extent of 125I-EPO endocytosis, as well as the reduction of cell
surface bound 125I-EPO, were essentially similar in Ba/F3 cells
and in COS 7 cells. Signi¢cant advantages of COS 7 cells are
their endurance of temperature shifts (4‡C to 37‡C), and much
higher expression levels of cell surface EPO-Rs as com-
pared to Ba/F3 cells. We thus compared the endocytosis of
125I-EPO by EPO-R mutants in transiently transfected COS
7 cells.
3.2. 125I-EPO internalization mediated by truncated EPO-Rs
A schematic representation of EPO-R mutants employed in
this study is depicted in Fig. 2. EPO-Rs truncated in their
cytoplasmic domain were constructed in order to identify re-
gions in this domain, involved in receptor internalization. In
addition, PB EPO-R (v281^300) [27], which lacks the JAK 2
binding domain, was employed.
125I-EPO binding and internalization were measured in
COS 7 cells transiently transfected with each EPO-R mutant
(Fig. 3A). To initially characterize EPO internalization by
the mutants, cells were incubated at 37‡C in the presence
of 125I-EPO for 90 min. Here, continuous internalization of
125I-EPO was measured, unlike the experiments described in
Figs. 1 and 4, which depict only one wave of 125I-EPO inter-
nalization. Cell surface and internalized 125I-EPO were deter-
mined as described in Section 2. This experiment revealed that
for three truncated EPO-Rs (1^267, 1^257 and 1^251 EPO-R)
the ratio of 125I-EPO speci¢cally internalized to that bound on
the cell surface over a 90 min incubation was about 0.3. This
ratio in wt EPO-R, PB (v281^300), 1^276 and 1^306 was
about 1. Noteworthy is the fact that the cell surface expres-
sion of these three endocytosis de¢cient EPO-Rs (1^251, 1^
257 and 1^267 EPO-R) under these conditions was typically
2^5-fold higher than that of the wt EPO-R, 1^306 and 1^276
EPO-R. Surface levels of PB EPO-R (v281^300) were usually
1.5^3-fold higher than that of wt EPO-R. A similar pattern of
125I-EPO binding and internalization was observed in Ba/F3
cells stably expressing wt, 1^251 and 1^257 EPO-Rs (Fig. 3B).
In agreement with Quelle et al. [28], we observed a signi¢cant
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Fig. 3. Binding and internalization of 125I-EPO by wt EPO-R and EPO-R mutants. COS 7 cells (A) or Ba/F3 cells (B) expressing wt EPO-R or
EPO-R mutants were incubated in the presence of 125I-EPO for 90 min at 37‡C. Subsequently cells were separated from non-bound radioactive
ligand. Cell surface bound 125I-EPO was removed by acid wash. Speci¢c binding was determined by subtracting the measured counts in the
presence of cold ligand from those in its absence. The ¢lled and empty bars represent cell surface bound and internalized 125I-EPO respectively.
Values represent the mean þ S.D. of triplicates. The ¢gure represents one representative experiment out of six experiments.
Fig. 2. Schematic representation of the EPO-R mutants used in this study. The EPO-R mutants employed in this study were (a) wt EPO-R,
(b) 1^306 EPO-R, (c) PB EPO-R (v281^300), (d) 1^251 EPO-R, (e) 1^257 EPO-R, (f) 1^267 EPO-R and (g) 1^276 EPO-R. The transmembrane
(TM) region is indicated.
I. Levin et al./FEBS Letters 427 (1998) 164^170166
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amount of 125I-EPO which was internalized by the cyto-
plasmically truncated mutants (1^251, 1^257 and 1^267
EPO-R). However, the ratio which we observed between the
internalized and cell surface EPO was typically lower for these
truncated mutants than for the wt EPO-R, suggesting that
their ability to internalize EPO is impaired.
To further characterize 125I-EPO internalization, we exam-
ined the kinetics of 125I-EPO internalization by wt EPO-R and
EPO-R mutants (Fig. 4). COS 7 cells were transiently trans-
fected with EPO-R cDNA, and 48 h later subjected to binding
and internalization of 125I-EPO. Binding of 125I-EPO was per-
formed at 4‡C for at least 10 h, thereby reaching saturation of
the surface receptors under conditions where virtually no en-
docytosis occurs. Following removal of free unbound ligand,
internalization of 125I-EPO was performed at 37‡C, for time
intervals between 0 to 20 min. These conditions are more
sensitive for detecting di¡erences in the rate and extent of
endocytosis between the various mutants than analysis of
steady-state endocytosis, because one is able to analyze the
initial steps of endocytosis independently of the later stage
of ligand internalization and degradation. The di¡erences in
the binding levels of 125I-EPO at 4‡C, between all the mutants
tested, maintained the pro¢le which was observed in Fig. 3.
Namely, 1^251, 1^257 and 1^267 EPO-R typically bound 2^
5-fold more 125I-EPO at the cell surface (data not shown). In
general, the rate of 125I-EPO endocytosis was similar for all
the mutants. However, EPO-R mutants which contained 4, 10
or 20 amino acids of the intracellular domain (1^251, 1^257
and 1^267 EPO-R respectively), internalized less 125I-EPO
after 20 min of incubation at 37‡C as compared to wt
EPO-R (Fig. 4). In cells expressing wt, 1^306, or PB EPO-R
(v281^300), 50% of surface bound 125I-EPO was internalized
after 20 min, as compared to 25% in those expressing 1^251,
1^257 or 1^267 EPO-R. Hence, our data indicate that the
sequence residing between amino acid residues 276 and 267
may be important for internalization of the EPO-R.
3.3. Expression and metabolism of EPO-Rs
Expression of the EPO-R mutants was examined by West-
ern blot analysis (Fig. 5). The EPO-Rs were immunoprecipi-
tated from lysates of transiently transfected COS 7 cells and
subjected to digestion with Endo H as indicated. All truncated
EPO-Rs, similarly to wt EPO-R and PB EPO-R (v281^300),
were poorly processed and their great majority was sensitive
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Fig. 5. Western blot analysis of wt EPO-R and EPO-R mutants in COS 7 cells. COS 7 cells expressing wt EPO-R were lysed in 500 Wl PBS
containing 1% Triton, 0.5% deoxycholate and 5 mM EDTA, in the presence of protease inhibitors. Cell lysates were immunoprecipitated with
antibodies against the extracellular domain of the EPO-R, followed by the addition of protein A Sepharose. Each sample was divided into two
aliquots which were incubated overnight at 37‡C in the presence or absence of Endo H. Subsequently, samples were separated by 10% SDS-
PAGE, and blotted onto nitrocellulose membrane ¢lter. The blot was probed with anti-EPO-R extracellular antibodies.
Fig. 6. Maturation and degradation of 1^257 EPO-R and wt EPO-R. COS 7 cells (A,B) or Ba/F3 cells (C,D) expressing wt EPO-R or 1^257
EPO-R were pulse labeled with [35S]methionine/cysteine (30 min or 15 min for COS 7 and Ba/F3 cells, respectively), and then chased for the in-
dicated periods of time in medium, as indicated. Detergent extracts of the cells were immunoprecipitated with an antiserum directed against the
EPO-R COOH terminus (for wt EPO-R), or against the extracellular domain (for 1^257 EPO-R). The immunoadsorbed material was divided
into two aliquots which were incubated overnight with either no addition (3) or with Endo H (+). Samples were then subjected to electropho-
resis using SDS-PAGE, £uorographed and subjected to autoradiography. Panels B and D represents densitometric scans of the autoradiograms
depicted in A and C respectively. Panel B represents bands corresponding to Endo H sensitive EPO-R in A, normalized to the amount of
Endo H sensitive EPO-R present at 0 h of chase, Endo H sensitive wt EPO-R (empty circles), and Endo H sensitive 1^257 EPO-R (full circles).
Panel D represents bands corresponding to Endo H sensitive wt EPO-R (empty circles), Endo H sensitive 1^257 EPO-R (full circles), Endo H
resistant EPO-R (empty triangles) and Endo H resistant 1^257 EPO-R (full triangles).
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to Endo H treatment (Fig. 5), corroborating the notion that
they were preferentially localized in the endoplasmic reticulum
(ER) [11]. Endo H-resistant EPO-R species were rarely de-
tected, as previously noted for the wt EPO-R expressed in
COS 7 cells [11]. Thus, the higher cell surface expression of
1^251, 1^257 and 1^267 EPO-Rs in COS 7 cells is not accom-
panied by the presence of detectable Golgi-processed EPO-Rs.
Increased metabolic stability of 1^251, 1^257 and 1^267
EPO-Rs may also contribute to their high cell surface expres-
sion. To address this possibility we compared the degradation
of one representative EPO-R mutant, 1^257 EPO-R, to that
of wt EPO-R. This experiment was performed both in tran-
siently transfected COS 7 cells and in Ba/F3 cells stably ex-
pressing these receptors. Cells were pulse labeled with
[35S]cysteine/methionine and chased in the presence of non-
labeled amino acids. At di¡erent times of the chase, cells
were lysed and the EPO-Rs immunoprecipitated with antibod-
ies directed against the extracellular domain of the EPO-R
(for 1^257 EPO-R) or antibodies directed against the cyto-
plasmic domain of the EPO-R (for wt EPO-R). This experi-
ment revealed that in COS 7 cells (Fig. 6A), similarly to the
Western blot analysis (Fig. 5), the Endo H sensitive species of
both wt EPO-R and 1^257 EPO-R were the predominant
EPO-R species present during all time points of the chase.
The half-lives of 1^257 EPO-R and of wt EPO-R were virtu-
ally identical, and were in the range of 1 h, as previously
demonstrated for the wt EPO-R [25,29]. In Ba/F3 cells stably
expressing the wt EPOR or 1^257 EPO-R, both Endo H sen-
sitive and Endo H resistant EPO-R species were detected (Fig.
6C). The half-lives of the Endo H sensitive wt and 1^257
EPO-Rs were similar, whereas the Endo H resistant 1^257
EPO-R was more stable than the Endo H resistant wt EPO-
R (Fig. 6D). The increased metabolic stability of Endo H
resistant 1^257 EPO-R may also contribute to the increased
cell surface expression of 1^257 EPO-R.
4. Discussion
This study demonstrates that cytoplasmically truncated
EPO-Rs containing, 4, 10 or 20 amino acids of the cytoplas-
mic domain, are expressed at high levels on the cell surface
and are de¢cient in their capacity to internalize membrane
bound 125I-EPO. While the kinetics of 125I-EPO internaliza-
tion by 1^251, 1^257 and 1^267 EPO-Rs were similar to wt
EPO-R, the level of internalized ligand by these mutants was
two-fold lower than that of wt EPO-R, PB EPO-R (v281^
300), 1^306 EPO-R or 1^276 EPO-R. Hence the sequence
FEGLFTTHK, £anked by amino acid residues 267 and 276,
may participate in downregulation of cell surface EPO-R. 1^
306 and 1^276 EPO-Rs endocytosed EPO similarly to wt
EPO-R, suggesting that the Tyr residues in the EPO-R cyto-
plasmic domain do not a¡ect the kinetics of EPO endocytosis.
In agreement with this result, an EPO-R mutant in which all
cytoplasmic tyrosine residues were replaced by phenylalanines
displayed 125I-EPO endocytosis with a similar kinetics to that
of the wt EPO-R (data not shown).
Truncated EPO-Rs (1^251, 1^257 and 1^267 EPO-Rs) were
expressed at higher levels than wt EPO-R 1^306 and 1^276
EPO-R, on the surface of transiently transfected COS 7 cells,
as monitored by surface bound 125I-EPO at 37‡C. A similar
pattern of cell surface EPO-R levels was also observed at 4‡C.
These results suggest that 1^251, 1^257 and 1^267 EPO-Rs
are de¢cient not only in receptor mediated endocytosis of the
ligand, but also in ligand independent, constitutive internal-
ization of the receptors. Interestingly, PB EPO-R (v281^300)
was also expressed at higher levels (1.5^3-fold) at the cell sur-
face compared to wt, 1^306 and 1^276. Yet, its ability to
endocytose EPO was not impaired (Figs. 3 and 4), indicating
that high cell surface expression of the receptor per se, does
not necessarily predict impaired ligand endocytosis. Further-
more, since the level of surface PB EPO-R (v281^300), was
similar to that of the endocytosis de¢cient EPO-R mutants,
the decrease in the ability of these mutants to endocytose
ligand is not due to saturation of the endocytic pathway,
resulting from increased expression of the receptors. Western
blot analysis of the EPO-R mutants expressed in COS 7 cells
indicated that all the mutants employed in this study were
poorly processed, as previously noted for the wt EPO-R
[11]. Thus, the higher cell surface expression of the truncated
EPO-R mutants and of PB EPO-R (v281^300) in COS 7 cells
was not accompanied by a detectable increase in the levels of
Golgi processed Endo H resistant EPO-R species. Increased
cell surface expression of 1^257 EPO-R does not result from
its faster transport to the membrane, since when cell surface
EPO-Rs were removed by trypsin treatment at 4‡C, the ki-
netics of recovery of wt and 1^257 EPO-R on the cell surface
was identical (data not shown).
Increased metabolic stability of EPO-R may also contribute
to increased cell surface expression of the EPO-R mutants. In
transiently transfected COS 7 cells, only the Endo H sensitive
forms of the EPO-Rs were detected (Fig. 6) probably due to
poor processing of the receptors [11]. In metabolic labeling
experiments, Endo H sensitive wt EPO-R and 1^257 EPO-R
displayed similar metabolic stabilities. This was also the case
for 1^251, 1^267 and PB (v281^300) EPO-R expressed in
COS 7 cells (data not shown). In Ba/F3 cells approximately
40% of both wt and 1^257 EPO-Rs acquired resistance to
Endo H. Endo H resistant 1^257 EPO-R was more stable
than Endo H resistant wt EPO-R, suggesting that cytoplasmic
residues may participate in receptor degradation, similarly to
the IL-2 L chain [20]. Hence, at this point we cannot exclude
the possibility that other receptor turnover processes may also
contribute to the increased cell surface expression and im-
paired ligand internalization by the EPO-R mutants which
lack the 9 amino acid motif.
The current study raises several intriguing questions. Do the
truncated receptors (1^251, 1^257 and 1^267 EPO-Rs) direct
internalized EPO to intracellular degradation by the same
pathway as wt EPO-R? We have shown that the sequence
FEGLFTTHK is necessary for EPO internalization, however
the question of whether it is su⁄cient to mediate internaliza-
tion of membrane proteins which are devoid of endogenous
internalization signals [15,30], remains to be addressed. The
phenylalanine (F) residues in the above sequence are probably
not involved in endocytosis since internalization of 125I-EPO
was not impaired in a full length EPO-R mutant in which the
two F residues were replaces by alanines (data not shown).
Studies are under way to determine the contribution of indi-
vidual amino acid residues in this sequence to endocytosis of
EPO.
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